Pharmaceutical and biotech science and business

Visit Pharma's Cutting Edge

In GLP-1 wars, Novo and others knock at Amylin s door Find Amylin moved to pricier digs

Posted on June 11, 2008

Above: NMR solution structure of exenatide from Ganfyd.orgtaspoglutide advancement announcementLead 6 results press release52-week data from Duration-1 trialA bit more excitement than usual surrounded this year s recently completed ADA annual meeting, with a flurry of news surrounding the GLP-1 mimetics and their brethren, the DPP-IV inhibitors.In my mind, the most interesting bit of news concerned progress on so-called exenatide LAR, a once-weekly formulation for sc injection of Amylin/Lilly exenatide. According to Amylin s website, the LAR program is being jointly managed by Amylin...

Original article link


clinical trial , disease , phase